Here we present experimental evidence that defines a molecular circuitry that contributes to aggressive and metastatic PCa and can be modulated by eNOS or SIRT1 inhibitors with potential impact on current therapies for PCa. The gene discussed is SIRT1; the disease is posterior cortical atrophy.